Erythropoietin Drugs Market by Product Types (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa) and Applications (Anemia, Kidney Disorders, Neural Disease and Wound healing) - Global Opportunity Analysis and Industry Forecast, 2013 - 2020 Update Available On-Demand
|
LI_1559
|
Pages: 115
|
Jan
2015 |
31029 Views
|
|
|
|
Author(s) :
Deepa Tatkare
|
Tables: 53
|
Charts: 31
|
Formats*:
|
|
Erythropoietin Drugs Market Overview:
Global Erythropoietin Drugs Market is expected to garner $11.9 billion by 2020, registering CAGR of 9.7% during the forecast period 2014 - 2020. Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis (production of red blood cells). These erythropoietin (EPO) drugs are used for treatment of chemotherapy-induced anemia; anemia is a common side-effect occurring due to chemotherapy of End Stage Renal Diseases (ESRD), cancer and HIV. Improved recombinant DNA technology has led to development of synthetic forms of erythropoietin such as epoetin alfa, epoetin beta, darbepoetin alfa, epoetin omega, and epoetin delta among the others.
The global EPO drugs market is thus driven by increasing number of patients suffering from anemic condition induced due to cancer, HIV and ESRD treatment; favorable reimbursements and increasing commercialization of EPO biosimilars. Amongst all synthetic erythropoietin products, Epoetin alfa and its advance version, Darbepoetin alfa, are the most popular drugs. Epoetin alfa and Darbepoetin alfa collectively accounted for ~80% of total EPO drugs market revenue. Amgen Inc. was first company to innovate Epoetin alfa and Darbepoetin alfa that are branded/patented as Epogen and Aranesp respectively. However, expiration of Amgen’s patent for Epogen has aided manufacturers of biosimilars to enter the EPO drugs market. Availability of numerous biosimilars has rendered low-cost option to the patients, therefore increased adoption rates for EPO drugs particularly in the developing regions.
Based on the applications, the global EPO drugs market is segmented into anemia associated with End Stage Renal Diseases (ESRD), cancer chemotherapy and, antiretroviral treatment (ART). Current research is focused toward expanding the applications of EPO drugs in other disease conditions such as neural diseases and wound healing.
GlobalErythropoietin drugs market is segmented based on geography into North America, Europe, Asia Pacific and LAMEA. Europe is the leading geographical market owing to favorable reimbursement policies and less stringent and speedy regulatory approvals for EPO drugs.
Key companies profiled in the report are, Amgen Inc., Johnson & Johnson, Hospira Inc., Roche, LG Life Sciences Ltd., Biocon, Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., and Celltrion, Inc.
.jpg)
Get more information on this report : Request Sample Pages
ERYTHROPOIETIN DRUGS MARKET KEY BENEFITS
- An in-depth analysis of current research and clinical developments within EPO drugs market is provided with key market dynamic factors that helps in understanding the behavior of market
- The report provides the quantitative analysis of the current market and estimations through 2013-2020 that assists in identifying the prevailing market opportunities to capitalize on
- Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework
- Comprehensive analysis of all geographic regions are provided that helps in determining the prevailing opportunities in these geographies
- Key market players within the EPO drugs market are profiled in the report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of global EPO drugs market
ERYTHROPOIETIN DRUGS MARKET KEY SEGMENTATION
The global EPO drugs market is segmented based on products, applications and geography.
BY PRODUCT TYPES
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
BY APPLICATIONS
- Anemia (Cancer and HIV treatment)
- Kidney Disorders (ESRD and Dialysis)
- Others (Neural Disease and Wound healing)
BY GEOGRAPHY
- North America
- Europe
- Asia-Pacific
- LAMEA
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION
1.1 Key Benefits
1.2 Key Market Segments
1.3 Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market beyond what to expect by 2025 ($Million)
2.1.1 Moderate growth scenario
2.1.2 Rapid growth scenario
2.1.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Evolution of Erythropoietin drugs
3.3 Erythropoietin Omega and Delta: pruned R&D pipeline drugs
3.4 Ethical considerations of erythropoietin drugs
3.5 Key findings
3.5.1 Top Factors Impacting for Global Erythropoietin Drugs Market
3.5.2 Top Investment Pockets for Global Erythropoietin Drugs Market
3.6 Value Chain Analysis
3.7 Key market player positioning (2014)
3.8 Product positioning for patented products (2014)
3.9 Clinical trials for EPO drug in neural diseases and wound healing
3.10 Competitive Intelligence on top three leaders (Amgen, J&J and Roche)
3.11 Market share analysis, 2013
3.12 Market dynamics
3.12.1 Drivers
3.12.1.1 Increasing number cases: including cancer,HIV, kidney disease and anaemia
3.12.1.2 Growing trends of commercialization for erythropoietin biosimilars
3.12.1.3 Readily available reimbursements and favorable government regulations
3.12.1.4 Increasing level of awareness about the benefits of EPO therapeutics
3.12.2 Restraints
3.12.2.1 Unaffordability of therapeutics
3.12.2.2 Longer duration of treatments
3.12.2.3 Adverse amount of side effects
3.12.3 Opportunities
3.12.3.1 Commercialization of darbepotin alfa biosimilar
3.12.3.2 Achieving Economies of scale across developed region with biosimilar version of EPO
CHAPTER 4 GLOBAL ERYTHROPOIETIN MARKET BY PRODUCTS
4.1 Epoetin-alfa
4.1.1 Historical Milestones
4.1.2 Commercial outlook
4.1.3 Approaches of clinical trials
4.1.4 Key market trends
4.1.5 Regulatory and reimbursement scenarios
4.1.6 Key growth factors and opportunities
4.1.7 Market size and forecast
4.2 Epoetin-beta
4.2.1 Historical Milestones
4.2.2 Approaches of clinical trials
4.2.3 Key market trends
4.2.4 Regulatory and reimbursement scenarios
4.2.5 Key growth factors and opportunities
4.2.6 Market size and forecast
4.3 Darbepoetin-alfa
4.3.1 Historical Milestones
4.3.2 Commercial outlook
4.3.3 Approaches of clinical trials
4.3.4 Key market trends
4.3.5 Regulatory and reimbursement scenarios
4.3.6 Key growth factors and opportunities
4.3.7 Market size and forecast
CHAPTER 5 GLOBAL ERYTHROPOIETIN MARKET BY APPLICATIONS
5.1 Anemia (Cancer and HIV treatment)
5.2 Kidney Disorders (ESRD and Dialysis)
5.3 Others (Neural Disease and Wound healing)
CHAPTER 6 GLOBAL ERYTHROPOIETIN MARKET BY GEOGRAPHY
6.1 North America
6.1.1 Key market trends
6.1.2 Reimbursement and regulations
6.1.3 Key growth factors and opportunities
6.1.4 Market size and forecast
6.2 Europe
6.2.1 Key market trends
6.2.2 Reimbursement and regulations
6.2.3 Key growth factors and opportunities
6.2.4 Market size and forecast
6.3 Asia-Pacific
6.3.1 Key market trends
6.3.2 Reimbursement and regulations
6.3.3 Key growth factors and opportunities
6.3.4 Market size and forecast
6.4 LAMEA
6.4.1 Key market trends
6.4.2 Reimbursement and regulations
6.4.3 Key growth factors and opportunities
6.4.4 Market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1 Amgen Inc.
7.1.1 Overview
7.1.2 Amgen Inc. snapshot
7.1.3 Financial performance
7.1.4 Operating Business Segment
7.1.5 SWOT analysis
7.2 Johnson and Johnson
7.2.1 Company overview
7.2.2 Johnson & Johnson snapshot
7.2.3 Operating Business Segment Overview
7.2.4 Financial performance
7.2.1 SWOT Analysis
7.3 Roche
7.3.1 Company overview
7.3.2 Roche Diagnostics snapshot
7.3.3 Operating Business Segment Overview
7.3.4 Financial performance
7.3.5 SWOT analysis of Roche Diagnostics
7.4 Hospira
7.4.1 Company overview
7.4.2 Hospira snapshot
7.4.3 Operating Business Segment Overview
7.4.4 Financial performance
7.4.5 SWOT analysis of Hospira
7.5 LG Life Sciences Ltd.
7.5.1 Company overview
7.5.2 LG Life Sciences Ltd. snapshot
7.5.3 Operating Business Segment Overview
7.5.4 Financial performance
7.5.5 SWOT analysis of LG Life Sciences Ltd.
7.6 Biocon
7.6.1 Company overview
7.6.2 Biocon snapshot
7.6.3 Operating Business Segment Overview
7.6.4 Financial performance
7.6.5 SWOT analysis of Biocon
7.7 Intas Pharmaceuticals
7.7.1 Company overview
7.7.2 Intas Pharmaceuticals snapshot
7.7.3 Operating Business Segment Overview
7.7.4 Financial performance
7.7.5 SWOT analysis of Intas Pharmaceuticals
7.8 Teva Pharmaceutical Industries Ltd.
7.8.1 Company overview
7.8.2 Teva Pharmaceutical Industries Ltd. snapshot
7.8.3 Operating Business Segment Overview
7.8.4 Financial performance
7.8.5 SWOT analysis of Teva Pharmaceutical Industries Ltd.
7.9 Ranbaxy Laboratories Ltd.
7.9.1 Company overview
7.9.2 Ranbaxy Laboratories Ltd. snapshot
7.9.3 Operating Business Segment Overview
7.9.4 Financial performance
7.9.5 SWOT analysis of Ranbaxy Laboratories Ltd.
7.10 Celltrion, Inc
7.10.1 Company overview
7.10.2 Celltrion, Inc. snapshot
7.10.3 Operating Business Segment Overview
7.10.4 Financial performance
7.10.5 SWOT analysis of Celltrion, Inc.
LIST OF TABLES
TABLE 1 GLOBAL ERYTHROPOIETIN MODERATE GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 2 GLOBAL ERYTHROPOIETIN RAPID GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 3 GLOBAL ERYTHROPOIETIN DIMINISHING GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 4 ERYTHROPOIETIN DRUGS (COMPANIES, BRAND NAME, AND VARIANTS)
TABLE 5 CLINICAL TRIALS OF ERYTHROPOEITIN FOR NEURAL DISEASES AND WOUND HEALING
TABLE 6 COMPETITIVE INTELLIGENCE ON TOP THREE LEADERS IN ERYTHROPOIETIN MARKET
TABLE 7 BIOSIMILAR VERSION OF ERYTHROPOIETIN COMMERCIALIZED AND UNDER DEVELOPMENT
TABLE 8 CMS REIMBURSEMENT CODES FOR ERYTHROPOIETIN
TABLE 9 ORIGINATOR EPOTIN ALFA PRODUCTS AND THEIR REVENUES IN 2013
TABLE 10 BIOSIMILARS OF EPOETIN ALFA: APPROVED OR IN DEVELOPMENT PHASE
TABLE 11 CLINICAL TRIALS OF EPOETIN ALFA
TABLE 12 CMS POLICY CODES FOR EPOETIN ALFA
TABLE 13 EPOTIN BETA PRODUCTS AND THEIR REVENUES (2013)
TABLE 14 CLINICAL TRIALS FOR EPOETIN BETA
TABLE 15 CMS POLICY CODES FOR EPOETIN BETA
TABLE 16 BIOSIMILARS OF DARBEPOETIN ALFA
TABLE 17 CLINICAL TRIALS FOR DARBEPOETIN ALFA
TABLE 18 CMS POLICY CODES FOR DARBEPOETIN ALFA
TABLE 19 GLOBAL CANCER AND HIV INDUCED ANEMIA ERYTHROPOIETIN DRUGS APPLICATION MARKET BY GEOGRAPHY, 2013-2020, $MILLION
TABLE 20 DIALYSIS POPULATION GROWTH RATE IN 2013
TABLE 21 ESTIMATED (ESRD PATIENT) POPULATION BASE TAKING EPO THERAPY, 2013-2020, (THOUSAND)
TABLE 22 GLOBAL ESRD AND DIALYSIS INDUCED ANEMIA ERYTHROPOIETIN DRUGS APPLICATION MARKET BY GEOGRAPHY, 2013-2020, $MILLION
TABLE 23 GLOBAL NEURAL DISEASES AND WOUND HEALING INDUCED ANEMIA ERYTHROPOIETIN DRUG APPLICATION MARKET BY GEOGRAPHY, 2013-2020, $MILLION
TABLE 24 GLOBAL ERYTHROPOETIN MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 25 SYNTHETIC ERYTHROPOIETIN MARKETED IN UNITED STATES
TABLE 26 REVISED USFDA GUIDELINES FOR THE DOSING OF ERYTHROPOIETIN STIMULATING AGENTS
TABLE 27 CMS POLICY DECISIONS FOR THE REIMBURSEMENT OF ERYTHROPOIETIN STIMULATING AGENTS
TABLE 28 NORTH AMERICA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013-2020 ($MILLION)
TABLE 29 EMA APPROVED ERYTHROPOIETIN (BIOSIMILARS AND INNOVATOR PRODUCTS) IN EUROPE
TABLE 30 EUROPE ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013-2020 ($MILLION)
TABLE 31 BIOSIMILARS MARKETED IN ASIA-PACIFIC
TABLE 32 ASIA-PACIFIC ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013-2020 ($MILLION)
TABLE 33 LAMEA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013-2020 ($MILLION)
TABLE 34 AMGEN INC. SNAPSHOT
TABLE 35 AMGEN INC. OPERATING BUSINESS SEGMENT
TABLE 36 JOHNSON & JOHNSON SNAPSHOT
TABLE 37 JOHNSON AND JOHNSON OPERATING SEGEMENTS
TABLE 38 ROCHE SNAPSHOT
TABLE 39 ROCHE OPERATING SEGEMENTS
TABLE 40 HOSPIRA SNAPSHOT
TABLE 41 HOSPIRA OPERATING SEGEMENTS
TABLE 42 LG LIFE SCIENCES LTD. DIAGNOSTICS SNAPSHOT
TABLE 43 LG LIFE SCIENCES LTD. DIAGNOSTICS OPERATING SEGEMENTS
TABLE 44 BIOCON SNAPSHOT
TABLE 45 BIOCON OPERATING SEGEMENTS
TABLE 46 INTAS PHARMACEUTICALS SNAPSHOT
TABLE 47 INTAS PHARMACEUTICALS OPERATING SEGEMENTS
TABLE 48 TEVA PHARMACEUTICAL INDUSTRIES LTD. SNAPSHOT
TABLE 49 TEVA PHARMACEUTICAL INDUSTRIES LTD. OPERATING SEGEMENTS
TABLE 50 RANBAXY LABORATORIES LTD. SNAPSHOT
TABLE 51 RANBAXY LABORATORIES LTD. OPERATING SEGEMENTS
TABLE 52 CELLTRION, INC. SNAPSHOT
TABLE 53 CELLTRION, INC. OPERATING SEGEMENTS
LIST OF FIGURES
FIG. 1 IMPACT ANALYSIS OF GLOBAL ERYTHROPOIETIN MARKET IN MODERATE GROWTH SCENARIO
FIG. 2 IMPACT ANALYSIS OF GLOBAL ERYTHROPOIETIN MARKET IN RAPID GROWTH SCENARIO
FIG. 3 IMPACT ANALYSIS OF GLOBAL ERYTHROPOIETIN MARKET IN DIMINISHING GROWTH SCENARIO
FIG. 4 GLOBAL ERYTHROPOIETIN (EPO) DRUGS MARKET DEFINITION
FIG. 5 EVOLUTION OF ERYTHROPOIETIN DRUGS
FIG. 6 TOP IMPACTING FACTORS OF GLOBAL ERYTHROPOIETIN DRUGS MARKET (2013-2020)
FIG. 7 TOP INVESTMENT POCKETS FOR GLOBAL ERYTHROPOIETIN DRUGS MARKET
FIG. 8 ERYTHROPOIETIN (EPO) VALUE CHAIN BY APPLICATION
FIG. 9 MARKET PLAYER POSITIONING OF ERYTHROPOIETIN DRUGS MARKET, 2014, (MILLION)
FIG. 10 ERYTHROPOIETIN PATENTED PRODUCT POSITIONING (2014)
FIG. 11 MARKET SHARE ANALYSIS OF GLOBAL ERYTHROPOIETIN DRUGS MARKET (2013)
FIG. 12 REGIONAL SALES OF NEORECORMON AND MIRCERA IN 2013 ($ MILLION)
FIG. 13 FORECAST ADOPTION OF EPO THERAPY BY GEOGRAPHY, 2013-2020 (% RATE)
FIG. 14 FINANCIAL REVENUE OF AMGEN INC. BY GEOGRAPHY (2013)
FIG. 15 FINANCIAL REVENUE OF AMGEN INC. BY PRODUCT PORTFOLIO (2013)
FIG. 16 SWOT ANALYSIS OF AMGEN INC.
FIG. 17 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY GEOGRAPHY (2013)
FIG. 18 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY BUSINESS UNITS (2013)
FIG. 19 SWOT ANALYSIS OF JOHNSON & JOHNSON
FIG. 20 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
FIG. 21 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY BUSINESS UNITS (2013)
FIG. 22 SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIG. 23 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
FIG. 24 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY BUSINESS UNITS (2013)
FIG. 25 SWOT ANALYSIS OF ROCHE
FIG. 26 SWOT ANALYSIS OF LG LIFE SCIENCES LTD.
FIG. 27 SWOT ANALYSIS OF HOSPIRA
FIG. 28 SWOT ANALYSIS OF INTAS PHARMACEUTICALS
FIG. 29 SWOT ANALYSIS OF TEVA PHARMACEUTICAL INDUSTRIES LTD.
FIG. 30 SWOT ANALYSIS OF RANBAXY LABORATORIES LTD.
FIG. 31 SWOT ANALYSIS OF CELLTRION, INC.
Commercialization of a potent version of Erythropoietin alfa namely Darbepotin alfa reveals lucrative opportunities within the EPO drugs market. Darbepotin alfa that is potent (as compared to other EPO drugs) is effective at smaller dosage, thus results lesser side effects than its peers. Hence, Darbepotin alfa is increasingly preferred by the customers (doctors). Also, patent protection for Darbepotin alfa will expire by 2016, hence, manufacturers of generic EPO drugs/biosimilars can target entry into this market.
In terms of applications, sale of EPO drugs targeted for treating kidney disorders (ESRD and dialysis) proves lucrative; as usage of EPO drugs is mandatory and irreplaceable (by indirect substitutes) for treating kidney disorders. In case of oncological disorders, usage of radiation therapy is increasingly replacing chemotherapy; declining usage of chemotherapy consequently reduces the demand for EPO drugs (in treatment of oncological disorders).
Geographically, the European market is attractive as the ease of commercialization of biosimilars is high in the European region; the region has favourable regulations in context of approvals.
Download Sample
Purchase Full Report of
Erythropoietin Drugs Market- Global Opportunity Analysis and Industry Forecast, 2013 - 2020
- Online Only
- $3,217
- Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
- $3,574
- Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
- $4,999
- Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
- $6,004
- Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF - $8,373
- Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Library Membership
- $0.00
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading instantly.
Buy Now
This title and over 12,000+ are available on the Avenue Library. Subscription @ $559.20833333333 T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.